“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
|Articles|January 1, 1999
Oncology NEWS International
- Oncology NEWS International Vol 8 No 1
- Volume 8
- Issue 1
Smoking by Pregnant Teens Trends Upward Again
HYATTSVILLE, Md-The number of teenagers who smoke while pregnant is on the rise again. Data from a new National Center for Health Statistics (NCHS) study show that smoking among pregnant women between the ages of 15 and 19 increased to 17.2% in 1995 and 1996 after declining for several years. Non-Hispanic whites, at 29%, had the highest rate of smoking among pregnant teenagers. The study found a significant decline overall in smoking by pregnant women, from almost 20% in 1990 to 14% in 1996.
Advertisement
HYATTSVILLE, MdThe number of teenagers who smoke while pregnant is on the rise again. Data from a new National Center for Health Statistics (NCHS) study show that smoking among pregnant women between the ages of 15 and 19 increased to 17.2% in 1995 and 1996 after declining for several years. Non-Hispanic whites, at 29%, had the highest rate of smoking among pregnant teenagers. The study found a significant decline overall in smoking by pregnant women, from almost 20% in 1990 to 14% in 1996.
Articles in this issue
almost 28 years ago
Pittsburgh to Build New Cancer Centeralmost 28 years ago
NCI Initiates Two High-Priority Tobacco Research Programsalmost 28 years ago
Breast Cancer Stamp Sells Wellalmost 28 years ago
Hospital Strategies To Prevent Invasive Aspergillosis Spreadalmost 28 years ago
‘Cancer Patients Should Be Assertive, Know Their Rights’almost 28 years ago
EBCTCG Update of Adjuvant Treatment for Early Breast Canceralmost 28 years ago
Younger Breast Cancer Patients at Increased Risk of Recurrencealmost 28 years ago
Six Named to National Cancer Advisory Boardalmost 28 years ago
Trial Uses Vitamin A To Prevent Lung Cancer in Former Smokersalmost 28 years ago
‘Medical School Curriculum Must Include Palliative Care’Advertisement
Related to this article
KEYNOTE-B49 data show pembrolizumab plus chemotherapy improved PFS but not OS in PD-L1–positive HR+/HER2– advanced breast cancer.
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
ASTRO now recommends moderate hypofractionation for all risk groups and SBRT as a standard option in low- and intermediate-risk localized prostate cancer.
Futibatinib, pemigatinib, and lirafugratinib showed similar response rates and progression-free survival at first FGFR inhibitor exposure in biliary tract cancers with FGFR alterations.
Frontline iza-bren plus pembrolizumab yielded a 57.9% ORR in recurrent or metastatic HNSCC at 2.5 mg/kg, the dose chosen for phase 3 study.
In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.
Data from the phase 3 OptiTROP-Lung06 trial may support sacituzumab tirumotecan plus pembrolizumab as a new frontline option for this NSCLC population.
Advertisement
Advertisement
Trending on CancerNetwork
1
Cardiac Assessment With Atrial Fibrillation and Closing Thoughts
2
Encorafenib/Binimetinib Plus Pembrolizumab Extends PFS in BRAF V600 Melanoma
3
Real-World Data on Cemiplimab Monotherapy Align With Prior NSCLC Studies
4
Prior ICI Exposure Linked to Higher Dermatitis Risk With Lirafugratinib in FGFR2-Altered Tumors
5